Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BIND Biosciences Presents Preclinical Data for Novel Nanomedicine, BIND-014, at American Chemical Society National Meeting

Abstract:
BIND Biosciences announced today the presentation of its Medicinal Nanoengineering™ platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug, BIND-014, scheduled to enter clinical trials later this year.

BIND Biosciences Presents Preclinical Data for Novel Nanomedicine, BIND-014, at American Chemical Society National Meeting

Cambridge, MA | Posted on August 23rd, 2010

BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung. In animal models of human cancers, BIND-014 was shown to deliver up to 20 times more docetaxel to the tumor site than an equivalent dose of Taxotere®. The increased accumulation of docetaxel at the site of disease was shown in preclinical models to lead to marked improvements in antitumor activity and tolerability.

At the ACS National Meeting, Dr. Jeff Hrkach, Senior Vice President of Pharmaceutical Sciences at BIND, will present the latest preclinical data showing the efficacy of BIND-014, as well as presenting results of preclinical studies using the company's Medicinal Nanoengineering proprietary technology for BIND's drug candidates in oncology, inflammatory diseases and cardiovascular disorders. The presentation will be part of a three-day symposium on the advancement of nanomedicine at the ACS National Meeting, taking place in Boston from August 22 through August 26. Dr. Hrkach's presentation, "High-precision therapeutics through Medicinal Nanoengineering," will be Tuesday, August 24 at 3:55 PM in The Westin Boston Waterfront, Grand Ballroom C.

In addition, both of BIND's scientific co-founders, Dr. Robert Langer, MIT David H. Koch Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Associate Professor, have been invited to present at the nanomedicine symposium at the ACS.

* Dr. Langer delivered the opening keynote address for the nanomedicine symposium, "Nanotechnology and its potential in medicine," on Sunday, August 22.

* Dr. Farokhzad will make a presentation, "Medical nanoengineering: Multifunctional polymeric nanoparticles for medical applications," on Monday, August 23, with the results and drug discovery translation of his pioneering academic research in nanomedicine technology.

"As our recent data show, BIND's Medicinal Nanoengineering approach has the potential to significantly improve upon the traditional drug development process and produce best-in-class new drugs," said Jeff Hrkach, Senior VP at BIND. "We have shown in preclinical studies with BIND-014 and other drug candidates that our platform can produce more effective, less toxic drugs by targeting our drug compounds precisely to the site of disease."

####

About BIND Biosciences
BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best-in-class drugs to provide significant improvement in the treatment of patients with serious diseases. BIND’s platform enables the design, engineering and manufacturing of therapeutic targeted nanoparticles with unprecedented control over drug pharmacokinetics, biodistribution and cell- or tissue-specific targeting. Medicinal Nanoengineering complements medicinal chemistry to enable predictable, cost effective and rapid development of breakthrough products with superior efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications or life cycle extension for mid- and late-stage products. BIND’s initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. BIND is working both on nanoengineered forms of approved drugs and with pharmaceutical partners on drugs in development. BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010.

BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer and Dr. Omid Farokhzad. BIND is backed by leading venture capital firms, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.

For more information, please click here

Contacts:
BIND Biosciences, Inc.
Andrea Franz, 617-491-3400

or
Media:
The Yates Network
Kathryn Morris, 845-635-9828

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Creation of coherent states in molecules by incoherent electrons October 21st, 2017

Novel 'converter' heralds breakthrough in ultra-fast data processing at nanoscale: Invention bagged four patents and could potentially make microprocessor chips work 1,000 times faster October 20th, 2017

Strange but true: turning a material upside down can sometimes make it softer October 20th, 2017

Leti Coordinating Project to Develop Innovative Drivetrains for 3rd-generation Electric Vehicles: CEA Tech’s Contribution Includes Liten’s Knowhow in Magnetic Materials and Simulation And Leti’s Expertise in Wide-bandgap Semiconductors October 20th, 2017

Nanomedicine

Spinning strands hint at folding dynamics: Rice University lab uses magnetic beads to model microscopic proteins, polymers October 17th, 2017

Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting(R) October 10th, 2017

Arrowhead to Present at Chardan Gene Therapy Conference October 3rd, 2017

'CRISPR-Gold' fixes Duchenne muscular dystrophy mutation in mice October 3rd, 2017

Announcements

Creation of coherent states in molecules by incoherent electrons October 21st, 2017

Novel 'converter' heralds breakthrough in ultra-fast data processing at nanoscale: Invention bagged four patents and could potentially make microprocessor chips work 1,000 times faster October 20th, 2017

Strange but true: turning a material upside down can sometimes make it softer October 20th, 2017

Leti Coordinating Project to Develop Innovative Drivetrains for 3rd-generation Electric Vehicles: CEA Tech’s Contribution Includes Liten’s Knowhow in Magnetic Materials and Simulation And Leti’s Expertise in Wide-bandgap Semiconductors October 20th, 2017

Events/Classes

Nanometrics Announces Preliminary Results for the Third Quarter of 2017: Quarterly Results Impacted by Delays in Revenue Recognition on Multiple Systems into Japan October 12th, 2017

More 22 of 59,885 Print all In new window Leti to Present Update of CoolCube/3DVLSI Technologies Development at 2017 IEEE S3S: Future Developments and Tape-Out Vehicles to Be Presented during Oct. 17 Workshop October 12th, 2017

Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting(R) October 10th, 2017

Arrowhead to Present at Chardan Gene Therapy Conference October 3rd, 2017

Nanobiotechnology

Spinning strands hint at folding dynamics: Rice University lab uses magnetic beads to model microscopic proteins, polymers October 17th, 2017

Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting(R) October 10th, 2017

Arrowhead to Present at Chardan Gene Therapy Conference October 3rd, 2017

'CRISPR-Gold' fixes Duchenne muscular dystrophy mutation in mice October 3rd, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project